For details please refer to the section Investors/Financial Statements, Reports and Presentations
GUIDANCE
Note: The Guidance FY 2023 envisages the full consolidation of Blampin and Capexo as from Jan.1,2023. % chg. are calculated on median values.
(*) Excluding possible LTI/MBO to mature in 2022 and 2023 but including annual accruals of LTI matured in 2020 and 2021 .
(**) Excluding the increase in fixed assets due to the application of IFRS 16 but including ESG related investments.
FINANCIAL HIGHLIGHTS
| Thousand of euro |
31.12.2021 |
31.12.2020 |
31.12.2019 |
| Net sales |
1.069.776 |
1.041.535 |
1.005.718 |
| Adjusted Ebitda* |
52.929 |
48.404 |
38.706 |
| % Adjusted Ebitda |
4,9% |
4,6% |
3,8% |
| Adjusted Ebit |
25.526 |
22.414 |
12.953 |
| Ebit |
23.135 |
18.763 |
8.378 |
| Profit/loss |
18.508 |
12.269 |
2.264 |
| Adjusted profit/loss |
19.093 |
13.979 |
5.280 |
| * Adjusted Ebitda: it’s determined by adding to the Operating Result (EBIT) the amounts for depreciation, amortization, and provisions, and excluding non-recurring costs/income and costs related to the Top management incentives |
| Thousand of euro |
31.12.2021 |
31.12.2020 |
31.12.2019 |
| Net Invested Capital |
260.199 |
263.423 |
277.830 |
| Total Shareholders’ Equity |
175.186 |
160.111 |
150.931 |
| Net Financial Position |
84.346 |
103.311 |
126.898 |
| Financial Ratios: |
|
|
|
| Net Financial Position/Total Shareholders’ Equity |
0,48 |
0,65 |
0,84 |
| Net Financial Position/Adjusted Ebitda |
1,59 |
2,13 |
3,28 |
